{
    "root": "c8ebdb5d-3f0a-4922-b475-89fc9c4b946a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KISQALI",
    "value": "20250225",
    "ingredients": [
        {
            "name": "RIBOCICLIB SUCCINATE",
            "code": "BG7HLX2919",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_230905"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        }
    ],
    "indications": {
        "text": "kisqali kinase inhibitor indicated : combination aromatase inhibitor adjuvant treatment adults hormone receptor ( hr ) -positive , human epidermal growth factor receptor 2 ( her2 ) -negative stage ii iii early breast cancer high risk recurrence . ( 1 ) treatment adults hr-positive , her2-negative advanced metastatic breast cancer combination : aromatase inhibitor initial endocrine-based therapy ; fulvestrant initial endocrine-based therapy following disease progression endocrine therapy . ( 1 )",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "kisqali tablets taken orally without food combination aromatase inhibitor fulvestrant . ( 2 ) early breast cancer recommended starting dose : 400 mg orally ( two 200 mg tablets ) taken daily without food 21 consecutive days followed 7 days treatment . ( 2.1 ) advanced metastatic breast cancer recommended starting dose : 600 mg orally ( three 200 mg tablets ) taken daily without food 21 consecutive days followed 7 days treatment . ( 2.1 ) dose interruption , reduction , and/or discontinuation may required based individual safety tolerability . ( 2.2 )",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "kisqali ( ribociclib ) tablets film-coated tablet contains 200 mg ribociclib free base . light greyish violet , round , curved beveled edge , debossed \u201c ric \u201d one side \u201c nvr \u201d side ; available : carton 3 blister packs ( 63 tablets total ) \u2013 blister pack contains 7-day supply 21 tablets ( 200 mg per tablet ) ( 600 mg daily dose ) . ndc 0078-0874-63 carton 3 blister packs ( 42 tablets total ) \u2013 blister pack contains 7-day supply 14 tablets ( 200 mg per tablet ) ( 400 mg daily dose ) . ndc 0078-0867-42 carton 1 blister pack ( 21 tablets total ) \u2013 blister pack contains 21-day supply 21 tablets ( 200 mg per tablet ) ( 200 mg daily dose ) . ndc 0078-0860-01 store refrigerated 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) . excursions permitted 2\u00b0c 15\u00b0c ( 36\u00b0f 59\u00b0f ) . dispensing , patients may store room temperature 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) 2 months . store tablets original blister pack .",
    "adverseReactions": "none .",
    "indications_original": "KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 )",
    "contraindications_original": "KISQALI tablets are taken orally with or without food in combination with an aromatase inhibitor or fulvestrant. ( 2 ) Early Breast Cancer Recommended starting dose: 400 mg orally (two 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment. ( 2.1 ) Advanced or Metastatic Breast Cancer Recommended starting dose: 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment. ( 2.1 ) Dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability. ( 2.2 )",
    "warningsAndPrecautions_original": "KISQALI (ribociclib) Tablets\n                  \n                  Each film-coated tablet contains 200 mg of ribociclib free base.\n                  Light greyish violet, round, curved with beveled edge, debossed with \u201cRIC\u201d on one side and \u201cNVR\u201d on the other side; available in:\n                  Carton of 3 blister packs (63 tablets total) \u2013 each blister pack contains a 7-day supply of 21 tablets (200 mg per tablet)(600 mg daily dose).\t\t\t\t\t\tNDC 0078-0874-63\n                  Carton of 3 blister packs (42 tablets total) \u2013 each blister pack contains a 7-day supply of 14 tablets (200 mg per tablet)(400 mg daily dose).\t\t\t\t\t\tNDC 0078-0867-42\n                  Carton of 1 blister pack (21 tablets total) \u2013 each blister pack contains a 21-day supply of 21 tablets (200 mg per tablet)(200 mg daily dose).\t\t\t\t\t\tNDC 0078-0860-01\n                  Store refrigerated at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Excursions permitted between 2\u00b0C and 15\u00b0C (36\u00b0F and 59\u00b0F).\n                  After dispensing, patients may store at room temperature at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) for up to 2 months.\n                  Store tablets in the original blister pack.",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "KISQALI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_230905"
        }
    ]
}